Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2025-12-30 @ 12:15 PM
Study NCT ID:
NCT00006456
Status:
COMPLETED
Last Update Posted:
2010-02-24
First Post:
2000-11-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
Sponsor:
Virginia Commonwealth University
Organization:
Study Overview
Official Title:
Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue.
PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
Detailed Description:
OBJECTIVES:
* Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors.
* Assess the toxicities of this treatment regimen in these patients.
* Determine tumor response and cause of death in these patients treated with this regimen.
OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
* Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors.
* Assess the toxicities of this treatment regimen in these patients.
* Determine tumor response and cause of death in these patients treated with this regimen.
OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| P30CA016059 | NIH | None | https://reporter.nih.gov/quic… | View |
| MCV-MCC-9812-2C | None | None | View | |
| NCI-V00-1612 | None | None | View |